National Pension Service Has $71.84 Million Holdings in Edwards Lifesciences Corporation $EW

National Pension Service grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 923,759 shares of the medical research company’s stock after purchasing an additional 24,070 shares during the quarter. National Pension Service owned about 0.16% of Edwards Lifesciences worth $71,841,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $28,000. True Wealth Design LLC grew its stake in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. NewSquare Capital LLC grew its position in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Rakuten Securities Inc. increased its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Edwards Lifesciences during the third quarter worth approximately $30,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Down 0.3%

Shares of NYSE:EW opened at $81.28 on Monday. The business has a 50 day moving average of $84.76 and a 200-day moving average of $81.02. The stock has a market cap of $47.17 billion, a PE ratio of 35.04, a P/E/G ratio of 3.13 and a beta of 0.94. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the business posted $0.67 EPS. The business’s revenue was up 14.7% compared to the same quarter last year. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on EW shares. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, December 17th. BTIG Research restated a “buy” rating and issued a $103.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. Citigroup reissued a “buy” rating and set a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. National Bankshares set a $92.00 target price on Edwards Lifesciences in a report on Friday, October 31st. Finally, Truist Financial set a $92.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,370,184.06. This trade represents a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 57,824 shares of company stock worth $4,863,323 over the last three months. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.